Structure Therapeutics Inc. (ADR)
General ticker "GPCR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.4B (TTM average)
Structure Therapeutics Inc. (ADR) follows the US Stock Market performance with the rate: 7.2%.
Estimated limits based on current volatility of 4.1%: low 35.95$, high 39.03$
Factors to consider:
- Total employees count: 220 (+35.0%) as of 2025
- Top business risk factors: Limited operating history, Significant losses, Trade tariffs, FDA approval delays, Manufacturing disruptions
- Price in estimated range
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [30.22$, 80.90$]
- 2026-12-31 to 2027-12-31 estimated range: [17.20$, 49.77$]
Financial Metrics affecting the GPCR estimates:
- Negative: with PPE of -45.8 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
- Negative: Shareholder equity ratio, % of 95.74 > 81.92
Short-term GPCR quotes
Long-term GPCR plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $102.78MM | $158.23MM | $176.56MM |
| Operating Income | $-102.78MM | $-158.23MM | $-176.56MM |
| Non-Operating Income | $13.39MM | $36.01MM | $35.87MM |
| R&D Expense | $70.10MM | $108.81MM | $225.25MM |
| Income(Loss) | $-89.38MM | $-122.22MM | $-140.69MM |
| Taxes | $0.24MM | $0.31MM | $0.52MM |
| Net Income(Loss)* | $-89.62MM | $-122.53MM | $-141.20MM |
| Stockholders Equity | $452.97MM | $864.84MM | $1,516.38MM |
| Assets | $482.02MM | $903.33MM | $1,583.92MM |
| Operating Cash Flow | $-79.49MM | $-116.64MM | $-222.20MM |
| Capital expenditure | $2.17MM | $1.29MM | $3.61MM |
| Investing Cash Flow | $-268.34MM | $-358.91MM | $89.80MM |
| Financing Cash Flow | $451.53MM | $515.26MM | $762.52MM |
| Earnings Per Share** | $-2.44 | $-2.33 | $-2.39 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.